In the world of biotech, we’ve seen stem cells pitched as everything from a medical miracle to a Silicon Valley spa treatment, but what Gallant Therapeutics just pulled off? That’s not hype. That’s precision. $18 million in fresh Series B fuel, led by Digitalis Ventures with returning conviction from BOLD Capital Partners and Hill Creek Partners, plus a serious nod from new investor NovaQuest Capital Management, says one thing loud and clear: regenerativemedicine for pets just got a real contender.
Let’s not gloss over it. Gallant isn’t slinging snake oil or repackaging yesterday’s science in tomorrow’s bottle. This San Diego-based outfit is building the veterinary equivalent of CRISPR, off-the-shelf, allogeneic stem cell therapies that don’t manage symptoms, they go straight for the root of disease. We’re talking uterine-derived MSCs harvested during routine spays, spun into 30 million doses from a single sample. No patient-specific matching. No invasive retrieval. Just ready-to-infuse, FDA-bound cell therapy that does more than wag the tail. It heals the dog.
None of this happens without Dr. Linda Black, DVM, PhD, who stepped into the CEO role after the tragic loss of founder Aaron Hirschhorn in 2021. Hirschhorn, who launched DogVacay and lived the pain of chronic back injuries firsthand, saw the parallel between his recovery and his arthritic dog’s suffering. Gallant was born from that intersection of personal grit and clinical vision, and it lives on with Black at the wheel. This isn’t a founder story polished for pitch decks. It’s one written in stem cells and persistence.
With Carolyn Wrightson, PhD as CTO, Steve Bach as CFO, Valentine Williams, DVM, MS, DACVS driving clinical development, and Rebecca Windsor, DVM, DACVIM engaging the frontlines, Gallant’s leadership team isn’t playing biotech bingo. They’ve stacked the board with science-first, execution-always talent.
And let’s not sleep on the business angle. This round didn’t close because the market’s feeling fuzzy about Fido. Gallant launched its JEDI pivotal study for Feline Chronic Gingivostomatitis (FCGS) last December and is on track for FDA conditional approval in early 2026. Translation? The first FDA-labeled, off-the-shelf stem cell therapy for veterinary use. You think pet owners dropping $100B+ annually aren’t ready to go beyond band-aid medicine? Gallant’s betting they are, and the market is agreeing.
The next horizon? Therapies for canine and feline osteoarthritis, atopic dermatitis, and chronic kidney disease, conditions where vets currently throw meds at symptoms and hope for the best. Gallant’s play is deeper: fix the cause, not just quiet the bark.
To every founder building something that outlives them, and every team bold enough to turn science fiction into tomorrow’s clinical standard, this is what it looks like when a mission refuses to die with its founder. It evolves.
